Studies have explored the correlation between KRAS mutation and COX-2 overexpression in colorectal tumors [52] and colon cancer cell lines [53], revealing that the activation of mutated KRAS increases COX-2 expression by enhancing the activity of mitogen-activated protein kinases (MAPKs). This evidence concerns the gene PTGS2 and colorectal neoplasm.